浆细胞而非CD20介导的B细胞清除可预防博来霉素诱导的肺纤维化
该研究在博来霉素诱导的小鼠肺纤维化模型中评估抗CD20 B细胞清除疗法的效果,发现抗CD20治疗未减少纤维化,但小鼠外周血和肺内仍保留高频CD19+CD138+浆细胞;IPF患者肺组织中也见高水平CD138+细胞;用硼替佐米清除浆细胞可减轻纤维化,提示浆细胞是肺纤维化的重要效应细胞。
要点
- 抗CD20清除成熟B细胞不能减轻博来霉素诱导的小鼠肺纤维化。
- 抗CD20处理后小鼠仍保留高频CD19+CD138+浆细胞。
- 硼替佐米清除浆细胞可减轻博来霉素诱导的肺纤维化。
核心结论
- 浆细胞而非CD20介导的B细胞清除在博来霉素诱导的肺纤维化中起保护作用。
- 浆细胞可能是肺纤维化发生和进展的重要效应细胞。
研究设计与样本
- 小鼠博来霉素诱导肺纤维化模型,评估抗CD20 B细胞清除疗法对纤维化的影响。
- 对小鼠外周血和肺驻留细胞进行免疫表型分析,并检测IPF患者肺组织CD138+细胞。
- 使用硼替佐米清除浆细胞,观察对博来霉素诱导肺纤维化的影响。
主要发现
- 抗CD20 B细胞清除未减少博来霉素诱导的小鼠肺纤维化。
- 抗CD20处理的小鼠外周血和肺驻留细胞中仍保留高频CD19+CD138+浆细胞。
- IPF患者肺组织中亦见高水平CD138+细胞,与小鼠模型一致。
- 硼替佐米清除浆细胞可降低博来霉素诱导的肺纤维化水平。
临床怎么用
- 在肺纤维化治疗策略中,靶向浆细胞可能比抗CD20 B细胞清除更有前景。
- 评估B细胞靶向治疗时需关注浆细胞是否被有效清除。
局限性
- 证据主要来自博来霉素诱导的小鼠肺纤维化模型,临床转化需进一步验证。
- IPF患者肺组织CD138+细胞为观察性发现,未报告其与临床结局的关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease associated with chronic inflammation and tissue remodelling leading to fibrosis, reduced pulmonary function, respiratory failure and death. Bleomycin (Blm)-induced lung fibrosis in mice replicates several clinical features of human IPF, including prominent lymphoid aggregates of predominantly B-cells that accumulate in the lung adjacent to areas of active fibrosis. We have shown previously a requirement for B-cells in the development of Blm-induced lung fibrosis in mice. To determine the therapeutic potential of inhibiting B-cell function in pulmonary fibrosis, we examined the effects of anti-CD20 B-cell ablation therapy to selectively remove mature B-cells from the immune system and inhibit Blm-induced lung fibrosis. Anti-CD20 B-cell ablation did not reduce fibrosis in this model; however, immune phenotyping of peripheral blood and lung resident cells revealed that anti-CD20-treated mice retained a high frequency of CD19+ CD138+ plasma cells. Interestingly, high levels of CD138+ cells were also identified in the lung tissue of patients with IPF, consistent with the mouse model. Treatment of mice with bortezomib, which depletes plasma cells, reduced the level of Blm-induced lung fibrosis, implicating plasma cells as important effector cells in the development and progression of pulmonary fibrosis.
引用
- Prêle CM, Miles T, Pearce DR, et al. Plasma cell but not CD20-mediated B-cell depletion protects from bleomycin-induced lung fibrosis. Eur Respir J. 2022. PMID: 35798357. doi:10.1183/13993003.01469-2021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。